The pharmaceutical industry’s latest antidepression drug marketing campaign is being launched with collaboration of the National Institute of Mental Health (NIMH) “Real Men, Real Depression campaign http://menanddepression.nimh.nih.gov/infopage.asp?ID=1
The pharmaceutical industry’s latest antidepression drug marketing campaign is being launched with collaboration of the National Institute of Mental Health (NIMH)—
"The federal government's campaign could discourage potential quitters who don't want to spend money on quitting aids or don't like the idea of treating their nicotine addiction with more nicotine."
“No general counsel or CEO wants to have to explain to his board why the company's name is appearing on the front page of a news article in a scandal…"
The FDA is salivating in expectation of increased funding from the drug industry–ostensibly to speed up the reviewing process for TV ads.
To gain insight into how a pharmaceutical giant is revving up itsr troops to lobby Congress against the legislation. See Pfizer CEO’s directive to the entire staff exhorting them to mobilize and lobby Congress to vote against drug price controls. http://www.pfizerfactfiction.com/mma/flash.html
The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
The New York Times reports that internal marketing documents show that “Eli Lilly encouraged primary care physicians to use Zyprexa, in patients who did not have either condition.”
Australian psychiatrist: "Does anyone else see tardive dysmentia after atypicalantipsychotics?"
U.S. Doctors are prescribing the antidepressant, Effexor (150mg) for infants under age one!
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
